

Assoc. Prof. ADEM ŞAHİN

Personal Information

Office Phone: [+90 228 214 2487](tel:+902282142487)

Email: adem.sahin@bilecik.edu.tr

Web: <https://avesis.bilecik.edu.tr/adem.sahin>

International Researcher IDs

ScholarID: eQTUE6wAAAAJ

ORCID: 0000-0002-3996-2931

Publons / Web Of Science ResearcherID: IYF-0830-2023

ScopusID: 57193089016

Yoksis Researcher ID: 24588

Education Information

Doctorate, Hacettepe University, Sağlık Bilimleri Enstitüsü, Farmasötik Teknoloji (Dr), Turkey 2013 - 2017

Undergraduate, Erciyes University, Eczacılık Fakültesi, Eczacılık Pr., Turkey 2006 - 2011

Dissertations

Doctorate, Polimerik Nanopartiküllerin Partikül Büyüklüğüne Bağlı Olarak Hücre İçine Alım Kinetikleri ve Mekanizmaları, Hacettepe University, Sağlık Bilimleri Enstitüsü, Farmasötik Teknoloji (Dr), 2017

Academic and Administrative Experience

Selcuk University, 2020 - 2021

Selcuk University, 2020 - 2021

Courses

MESLEKİ TERMİNOLOJİ, Associate Degree, 2021 - 2022

İLAÇ RUHSATLANDIRMA VE PATENT, Undergraduate, 2021 - 2022

Meslekte Etik, Associate Degree, 2021 - 2022

İlaç Şekilleri ve Tıbbi Malzeme I, Associate Degree, 2021 - 2022

Kariyer Planlama ve Geliştirme, Associate Degree, 2021 - 2022

Medikal Lojistik Yönetimi, Associate Degree, 2021 - 2022

FARMASÖTİK TEKNOLOJİ I LABORATUVARI, Undergraduate, 2020 - 2021, 2019 - 2020

Eczane Teknikerleri için Toksikoloji, Associate Degree, 2020 - 2021

Eczane Teknikerleri için Temel Hesaplamalar ve Uygulamaları, Associate Degree, 2020 - 2021

FARMASÖTİK TEKNOLOJİ III, Undergraduate, 2020 - 2021

FARMASÖTİK TEKNOLOJİ I, Undergraduate, 2020 - 2021, 2019 - 2020

İlaç Şekilleri ve Tıbbi Malzeme II, Associate Degree, 2020 - 2021

FARMASÖTİK TEKNOLOJİ III LABORATUVARI, Undergraduate, 2020 - 2021

İLAÇ GELİŞTİRMEDE TEMEL KAVRAMLAR, Undergraduate, 2019 - 2020

Published journal articles indexed by SCI, SSCI, and AHCI

- I. **An all-in-one nanoparticle for overcoming drug resistance: doxorubicin and elacridar co-loaded folate receptor targeted PLGA/MSN hybrid nanoparticles**
TONBUL H., ŞAHİN A., ÖZTÜRK S. C., ULTAV G., Tavukçuoğlu E., Akbaş S., AKTAŞ Y., ESENDAĞLI G., ÇAPAN Y.
Journal of Drug Targeting, vol.32, no.9, pp.1101-1110, 2024 (SCI-Expanded)
- II. **Targeted siRNA lipid nanoparticles for the treatment of KRAS-mutant tumors**
Anthiya S., ÖZTÜRK S. C., Yanık H., Tavukcuoglu E., ŞAHİN A., Datta D., Charisse K., Álvarez D. M., Loza M. I., Calvo A., et al.
Journal of Controlled Release, vol.357, pp.67-83, 2023 (SCI-Expanded)
- III. **Intraperitoneal administration of PLGA nanoparticles could deliver the cargo to tumor-associated macrophages with less spreading peritoneal macrophages in the treatment of peritoneal carcinomatosis**
ŞAHİN A., ÖZTÜRK S. C.
Journal of Drug Delivery Science and Technology, vol.77, 2022 (SCI-Expanded)
- IV. **Evaluation of burn wound healing activity of thermosensitive gel and PLGA nanoparticle formulation of quercetin in Wistar albino rats**
Cetin N., Menevse E., Celik Z. E., Ceylan C., Rama S. T., Gultekin Y., Tekin T., ŞAHİN A.
Journal of Drug Delivery Science and Technology, vol.75, 2022 (SCI-Expanded)
- V. **pH-sensitive chitosan-PEG-decorated hollow mesoporous silica nanoparticles could be an effective treatment for acute myeloid leukemia (AML)**
Ultav G., TONBUL H., Tavukcuoglu E., OZTURK S. E., Akbas S., ŞAHİN A., ESENDAĞLI G., ÇAPAN Y.
Journal of Nanoparticle Research, vol.24, no.2, 2022 (SCI-Expanded)
- VI. **Development of curcumin and docetaxel co-loaded actively targeted PLGA nanoparticles to overcome blood brain barrier**
Seko I., TONBUL H., Tavukçuoğlu E., ŞAHİN A., Akbas S., Yanık H., ÖZTÜRK S. C., ESENDAĞLI G., Khan M., ÇAPAN Y.
Journal of Drug Delivery Science and Technology, vol.66, 2021 (SCI-Expanded)
- VII. **Folic acid decoration of mesoporous silica nanoparticles to increase cellular uptake and cytotoxic activity of doxorubicin in human breast cancer cells**
TONBUL H., ŞAHİN A., Tavukcuoglu E., Ultav G., Akbas S., AKTAŞ Y., ESENDAĞLI G., ÇAPAN Y.
Journal of Drug Delivery Science and Technology, vol.63, 2021 (SCI-Expanded)
- VIII. **Combination of Paclitaxel and R-flurbiprofen loaded PLGA nanoparticles suppresses glioblastoma growth on systemic administration**
Caban-Toktas S., ŞAHİN A., Lule S., ESENDAĞLI G., VURAL İ., Karlı Oguz K., Soylemezoglu F., Mut M., DALKARA T., Khan M., et al.
International Journal of Pharmaceutics, vol.578, 2020 (SCI-Expanded)
- IX. **Combination drug delivery with actively-targeted PLGA nanoparticles to overcome multidrug resistance in breast cancer**
TONBUL H., ŞAHİN A., Tavukcuoglu E., ESENDAĞLI G., ÇAPAN Y.
Journal of Drug Delivery Science and Technology, vol.54, 2019 (SCI-Expanded)
- X. **Synthesis of small-sized mesoporous silica nanoparticles by experimental design and characterization for further drug delivery**
TONBUL H., Ultav G., Akbaş S., ŞAHİN A., AKTAŞ Y., ÇAPAN Y.
Latin American Journal of Pharmacy, vol.38, no.11, pp.2204-2210, 2019 (SCI-Expanded)
- XI. **Development and in vitro evaluation of doxorubicin and celecoxib co-loaded bone targeted nanoparticles**
Kozlu S., ŞAHİN A., Ultav G., YERLİKAYA F., Calis S., ÇAPAN Y.

- Journal of Drug Delivery Science and Technology, vol.45, pp.213-219, 2018 (SCI-Expanded)
- XII. **Design and in vitro evaluation of tenofovir-loaded vaginal gels for the prevention of HIV infections**
TİMUR S. S., ŞAHİN A., AYTEKİN E., ÖZTÜRK N., Polat K. H., Tezel N., GÜRSOY R. N., Çalış S.
Pharmaceutical Development and Technology, vol.23, no.3, pp.301-310, 2018 (SCI-Expanded)
- XIII. **Characterization of bevacizumab by dynamic light scattering while maintaining its native structure**
Akbas S., ŞAHİN A., Calis S., Oncel H., ÇAPAN Y.
Pharmazie, vol.73, no.7, pp.369-374, 2018 (SCI-Expanded)
- XIV. **A small variation in average particle size of PLGA nanoparticles prepared by nanoprecipitation leads to considerable change in nanoparticles' characteristics and efficacy of intracellular delivery**
ŞAHİN A., ESENDAĞLI G., YERLİKAYA F., Caban-Toktas S., Yoyen-Ermis D., Horzum U., AKTAŞ Y., Khan M., Couvreur P., ÇAPAN Y.
Artificial Cells, Nanomedicine and Biotechnology, vol.45, no.8, pp.1657-1664, 2017 (SCI-Expanded)
- XV. **Evaluation of brain-targeted chitosan nanoparticles through blood-brain barrier cerebral microvessel endothelial cells**
ŞAHİN A., Yoyen-Ermis D., Caban-Toktas S., Horzum U., AKTAŞ Y., Couvreur P., ESENDAĞLI G., ÇAPAN Y.
Journal of Microencapsulation, vol.34, no.7, pp.659-666, 2017 (SCI-Expanded)
- XVI. **Using PVA and TPGS as combined emulsifier in nanoprecipitation method improves characteristics and anticancer activity of ibuprofen loaded PLGA nanoparticles**
ŞAHİN A., Spiroux F., Guedon I., Arslan F., SARCAN BOZKIR E. T., ÖZKAN T., Colak N., YÜKSEL S., ÖZDEMİR S., ÖZDEMİR B., et al.
Pharmazie, vol.72, no.9, pp.525-528, 2017 (SCI-Expanded)
- XVII. **Development and validation of a LC-FL method for the simultaneous determination of doxorubicin and celecoxib in nanoparticulate fixed dose combination (NanoFDC)**
Kozlu S., ŞAHİN A., Calis S., ÇAPAN Y.
Pharmazie, vol.72, no.10, pp.568-570, 2017 (SCI-Expanded)

Articles Published in Other Journals

- I. **Thermosensitive gel of pomegranate peel extract as alternative for the treatment of local infections**
Sahin A., Gül Ü. D., Bayazit G., Kaynak M. S.
ACTA Pharmaceutica Scientia, vol.62, no.3, pp.647-659, 2024 (Scopus)
- II. **Comparative evaluation of lyophilized voriconazole formulations marketed in European Union**
ŞAHİN A., YAĞ ÇİLİNGİROĞLU G., ÇATAK T., ULUSOY S., GÜL Ü. D., ÖZLEM GÜNDOĞDU S.
Journal of research in pharmacy (online), vol.27, no.1, pp.120-129, 2023 (Scopus)
- III. **Silica nanoparticle synthesis by experimental design for drug and gene delivery applications**
Ultav G., TONBUL H., ŞAHİN A., ÇAPAN Y.
Journal of research in pharmacy (online), vol.27, no.1, pp.12-22, 2023 (Scopus)
- IV. **Preface**
ÇAPAN Y., ŞAHİN A., TONBUL H.
Drug Delivery with Targeted Nanoparticles: In Vitro and in Vivo Evaluation Methods, vol.25, pp.2, 2021 (Scopus)
- V. **Brain-targeted nanoparticles to overcome the blood-brain barrier**
Seko İ., ŞAHİN A., TONBUL H., ÇAPAN Y.
Journal of Pharmaceutical Technology, vol.1, no.1, pp.23-39, 2020 (Peer-Reviewed Journal)
- VI. **Development of paclitaxel and flurbiprofen coloaded PLGA nanoparticles: understanding critical formulation and process parameters using Plackett- Burman design**
ŞAHİN A., TOKTAŞ S., TONBUL H., YERLİKAYA F., AKTAŞ Y., ÇAPAN Y.
JOURNAL OF PHARMACY OF ISTANBUL UNIVERSITY, vol.49, no.3, pp.161-166, 2019 (Peer-Reviewed Journal)
- VII. **Nanosystems for drug delivery**
TOKTAŞ S., AYTEKİN E., ŞAHİN A., ÇAPAN Y.
OA Drug Design and Delivery, vol.24, pp.435-444, 2014 (Scopus)

Books & Book Chapters

- I. **Nanoparticles for the Treatment of Peritoneal Carcinomatosis**
Karasu İ., Ulusoy S., Yağ Çilingirođlu G., ŞAHİN A.
in: Horizons in Cancer Research Volume 86, Hiroto S. Watanabe, Editor, Nova Science Publishers, pp.172-192, 2023
- II. **Overcoming the challenges of drug resistance through combination drug delivery approach**
TONBUL H., ŞAHİN A., ÇAPAN Y.
in: Combination Drug Delivery Approach as an Effective Therapy for Various Diseases, Prashant Kesharwani, Editor, Academic Press , pp.31-46, 2022
- III. **PLGA-Based Nanomaterials for Cancer Therapy**
GÜLTEKİN Y., TEKİN T., KOÇAŞ M., ÇAPAN Y., ŞAHİN A.
in: Nanotechnology for Biomedical Applications, Sreerag Gopi, Preetha Balakrishnan, Nabisab Mujawar Mubarak, Editor, Springer Singapore, pp.263-284, 2022

Refereed Congress / Symposium Publications in Proceedings

- I. **DEVELOPMENT OF PASTILLES CONTAINING POMEGRANATE PEEL EXTRACT**
ŞAHİN A.
6th INTERNATIONAL HEALTH SCIENCE AND LIFE CONGRESS, Burdur, Turkey, 2 - 05 March 2023, vol.442
- II. **CNT-02 is a potent candidate drug for the elimination of lung damage caused by COVID-19**
Yağ Çilingirođlu G., Çatak T., Karasu İ., Ulusoy S., Özlem Gündođdu S., ŞAHİN A.
11th International Drug Chemistry Congress, 09 March 2023
- III. **Evaluation of pomegranate peel extract and its thermosensitive gel formulation for the treatment of oral infections**
ŞAHİN A., BAYAZIT G., GÜL Ü. D.
5th International Eurasian Conference on Biological and Chemical Sciences (EurasianBioChem 2022), Turkey, 23 November 2022
- IV. **IN VIVO EVALUATION OF DOXORUBICIN AND ELACRIDAR CO-LOADED PLGA/SILICA HYBRID NANOPARTICLES AGAINST MULTIDRUG RESISTANT BREAST CANCER**
TONBUL H., ŞAHİN A., ÖZTÜRK S. C., ULTAV G., ESENDAĞLI G., ÇAPAN Y.
9th BBBB International Conference on Pharmaceutical Sciences, Ljubljana, Slovenia, 15 - 17 September 2022, pp.79-80
- V. **PRODUCTION OF MELOXICAM NANOCRYSTALS BY NANOPRECIPITATION METHOD**
ŞAHİN A., TONBUL H.
The Sixth International Symposium on Pharmaceutical and Biomedical Sciences, Gaziantep, Turkey, 26 - 28 May 2022, pp.73
- VI. **CRITICAL STEPS OF SOLUTION PREPARATION PROCESS FOR PARENTERAL DRUGS: TIGECYCLINE CASE**
ŞAHİN A.
The Sixth International Symposium on Pharmaceutical and Biomedical Sciences, Gaziantep, Turkey, 26 - 28 May 2022, pp.72
- VII. **Bevacizumab loaded nanocapsules: cytotoxicity and internalization in lung and pancreatic cancer spheroids**
Fernandez-Marino I., Tavukçuođlu E., Yanık H., ŞAHİN A., ESENDAĞLI G., Crecente-Campo J., Alonso M. J.
XIIIth Spanish-Portuguese Conference on Controlled Drug Delivery, 24 January 2020
- VIII. **PREPARATION OF PLGA NANOPARTICLES WITH DIFFERENT SURFACTANTS AS DRUG DELIVERY SYSTEM**
TONBUL H., ŞAHİN A.
GEVHER NESİBE4. ULUSLARARASI SAĞLIK BİLİMLERİ KONGRESİ, Ankara, Turkey, 22 - 23 November 2019

- IX. FOLIC ACID CONJUGATED MESOPOROUS SILICA NANOPARTICLES FOR ENHANCED THERAPEUTIC EFFICACY OF DOXORUBICIN IN BREAST CANCER**
TONBUL H., ULTAV G., AKBAŞ S., ŞAHİN A., TAVUKÇUOĞLU E., AKTAŞ Y., ESENDAĞLI G., ÇAPAN Y.
8th BBBB Conference on Pharmaceutical Sciences, 14 - 16 October 2019
- X. PREPARATION OF ACTIVE TARGETED POLY(LACTIC-CO-GLYCOLIC ACID) NANOPARTICLES WITH OLEYL CYSTEINEAMIDE**
AKBAŞ S., ULTAV G., ŞAHİN A., TAVUKÇUOĞLU E., TONBUL H., ESENDAĞLI G., ÇAPAN Y.
8th BBBB Conference on Pharmaceutical Sciences, 14 - 16 October 2019
- XI. Folic Acid Conjugated Mesoporous Silica Nanoparticles For Enhanced Therapeutic Efficacy of Doxorubicin In Breast Cancer**
TONBUL H., AKBAŞ S., ULTAV G., ŞAHİN A., TAVUKÇUOĞLU E., AKTAŞ Y., ESENDAĞLI G., ÇAPAN Y.
8th BBBB Conference on Pharmaceutical Sciences, 14 - 16 October 2019, vol.1, pp.184-186
- XII. REVERSAL OF DRUG RESISTANCE IN EMT6/AR1 CELL LINE BY A CHEMICAL MODULATOR: ELACRIDAR**
TONBUL H., AKBAŞ S., ULTAV G., ŞAHİN A., ÇAPAN Y.
International Multidisciplinary Symposium on Drug Research and Development (DRD)-2019, 1 - 03 July 2019
- XIII. GX-G3, a long-acting G-CSF, compared with pegfilgrastim in reducing duration of severe neutropenia after chemotherapy for non-Hodgkin's lymphoma.**
Ertan-Ahmed S., Kiehl M. G., Radinoff A., Graklanov V., Tzvetkov N., Mihăescu R., ÖZATLI D., ATALAY F., TURGUT B., Cho S., et al.
2019 ASCO Annual Meeting I, 31 May 2019
- XIV. Preparation, Characterization, Cytotoxicity Evaluations of Folic Acid Conjugated Mesoporous Silica Nanoparticles**
TONBUL H., ULTAV G., AKBAŞ S., ŞAHİN A., TAVUKÇUOĞLU E., ESENDAĞLI G., AKTAŞ Y., ÇAPAN Y.
19th International Pharmaceutical Technology Symposium-IPTS 2018, 17 September 2018
- XV. A COMPERISON OF PLGA NANOPARTICLE PREPARATION METHODS FOR BEVACIZUMAB ENCAPSULATION**
AKBAŞ S., ULTAV G., TONBUL H., ŞAHİN A., ÇAPAN Y.
12th International Symposium on Pharmaceutical Sciences (ISOPS), 26 - 29 June 2018
- XVI. DEVELOPMENT AND EVALUATION OF SILICA NANOPARTICLES USING A QUALITY BY DESIGN APPROACH**
TONBUL H., AKBAŞ S., ULTAV G., ŞAHİN A., AKTAŞ Y., ÇAPAN Y.
EUFEPS Annual Meeting 2018, 24 - 26 May 2018
- XVII. IN VITRO EVALUATION OF PACLITAXEL LOADED MESOPOROUS SILICA NANOPARTICLES**
TONBUL H., AKBAŞ S., ULTAV G., ŞAHİN A., AKTAŞ Y., ÇAPAN Y.
EUFEPS Annual Meeting 2018, 24 - 26 May 2018
- XVIII. SYNTHESIS AND CHARACTERIZATION OF SILICA NANOPARTICLES: OBTAINING NANOPARTICLES SMALLER THAN 100 NM**
TONBUL H., AKBAŞ S., ULTAV G., ŞAHİN A., KAYNAK M. S., AKTAŞ Y., ÇAPAN Y.
2nd International Gazi Symposium Series, 11 - 13 October 2017
- XIX. DEVELOPMENT AND IN VITRO EVALUATION OF PH TRIGGERED HOLLOW SILICA NANOPARTICLES AS A DRUG DELIVERY SYSTEM**
ULTAV G., AKBAŞ S., TONBUL H., ŞAHİN A., ÇAPAN Y.
2nd International Gazi Pharma Symposium Series (GPSS-2017), 11 - 13 October 2017
- XX. CHARACTERIZATION OF BEVACIZUMAB BY DYNAMIC LIGHTSCATTERING TECHNIQUE**
AKBAŞ S., ULTAV G., TONBUL H., ŞAHİN A., ÇAPAN Y.
2nd International Gazi Pharma Symposium Series (GPSS-2017), 11 - 13 October 2017
- XXI. Transferrine hedeflendirilmiş paklitaksel yüklü PLGA nanopartiküllerinin meme kanserindeki etkinliği**
TONBUL H., ŞAHİN A., ÖZTÜRK N., VURAL İ., KAYNAK M. S., ÇAPAN Y.
1. Anadolu Üniversitesi Eczacılık Fakültesi Sempozyumu (ANES), Turkey, 1 June - 02 January 2017

- XXII. **Comparing Intracellular Delivery of PLGA and Chitosan Nanoparticles: Lessons and Challenges**
ŞAHİN A., YERLİKAYA F., AKTAŞ Y., ESENDAĞLI G., ÇAPAN Y.
GPEN 2016, Kansas, United States Of America, 9 - 12 November 2016
- XXIII. **Co Encapsulation Studies of Doxorubicin and Celecoxib in PLGA Nanoparticles**
Kozlu S., ŞAHİN A., Sevda Ş., Yerlikaya F., ÇAPAN Y.
18th International Pharmaceutical Technology Symposium-IPTS 2016, 18 September 2016 - 21 September 2016
- XXIV. **Development and in vitro evaluation of transferrin targeted PLGA nanoparticle**
TONBUL H., ŞAHİN A., KAYNAK M. S., ÇAPAN Y.
18th International Pharmaceutical Technology Symposium-IPTS 2016, 18 September 2016
- XXV. **Intracellular delivery and intraperitoneal retention of different sized PLGA nanoparticles prepared by nanoprecipitation method**
ŞAHİN A., ESENDAĞLI G., YERLİKAYA F., KOZLU S., YÖYEN ERMİŞ D., Horzum U., AKTAŞ Y., Khan M., Couvreur P., ÇAPAN Y.
18th International Pharmaceutical Technology Symposium-IPTS 2016, 18 September 2016
- XXVI. **PREPARATION AND IN VITRO EVALUATION OF ZICONOTIDE LOADED PLGA AND CHITOSAN NANOPARTICLES**
ŞAHİN A., TOKTAŞ S., AKTAŞ Y., ÇAPAN Y.
Barcelona BioMed Conference Blood Brain Barrier, 2 - 04 November 2015
- XXVII. **Effects of Combined Surfactants in the Formulation of Docetaxel Loaded PLGA Nanoparticles**
GULBAİRA A. K., TOKTAŞ S., ŞAHİN A., ÇAPAN Y.
American Association of Pharmaceutical Scientists, 25 - 29 October 2015
- XXVIII. **Particle Size Optimization of Ibuprofen Loaded PLGA Nanoparticles Using Box Behnken Design**
ŞAHİN A., TOKTAŞ S., AKTAŞ Y., ÇAPAN Y.
American Association of Pharmaceutical Scientists Annual Meeting 2015, 25 - 29 October 2015
- XXIX. **Determination of Critical Parameters of Paclitaxel and Flurbiprofen Co-Loaded PLGA Nanoparticles Prepared by Nanoprecipitation**
ŞAHİN A., TOKTAŞ S., Abdykerim Kyzy G., YERLİKAYA F., AKTAŞ Y., ÇAPAN Y.
American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition 2015, 25 - 29 October 2015
- XXX. **In Vitro and In Vivo Evaluation of Paclitaxel and R-Flurbiprofen Loaded Chitosan Coated PLGA Nanoparticles**
TOKTAŞ S., LÜLE S., ŞAHİN A., KARA A., PEHLİVAN S., VURAL İ., KARLI OĞUZ H. K., MUT AŞKUN M., ÇAPAN Y.
American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition 2015, 25 - 29 October 2015
- XXXI. **Inhibition Of Microbial Leakage at Implant-Abutment Interface with Chitosan Gels**
TOKTAŞ S., ÇOPUROĞLU S., Erdoğan C., ŞAHİN A., SAĞIROĞLU M., ÇAPAN Y., AKTAŞ A.
American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition 2014, 02 November 2014
- XXXII. **Formulation and In Vitro Evaluation of Nanoparticles Containing Docetaxel**
Babat D., TOKTAŞ S., ŞAHİN A., YERLİKAYA F., VURAL İ., ÇAPAN Y.
American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition 2014, 02 November 2014
- XXXIII. **A Pharmacy in James Joyce's Ulysses: The Sweny's Pharmacy-James Joyce'un Ulysses Eserinde Bir Eczane: Sweny'nin Eczanesi**
ŞAHİN A.
XI. National Conference on the History of Turkish Pharmacy, Kayseri, Turkey, 25 - 28 May 2014

Supported Projects

ŞAHİN A., GÜL Ü. D., BAYAZIT G., Project Supported by Higher Education Institutions, Bilecik'de Yetiştirilen Narlar

Kullanılarak Tedavi Edici Özellięe Sahip Nar Pastillerinin Geliştirilmesi ve Üretilmesi, 2022 - 2023

Yaę Çilingiroęlu G., Karasu İ., AKBAŞ S., ŞAHİN A., Project Supported by Other Private Institutions, Antifungal Etkili Mikafungin, Anidulafungin ve Vorikonazol Etkin Maddeli İlaçların Avrupa'da Kullanılma Sunulmak Üzere Geliştirilmesi ve CNT-02 Kodlu COVID-19 Tedavisinde Faz 2 Çalışmaları Süren İlaç Etkin Maddesinin Yeni Formülasyonlarının Hazırlanması, 2021 - 2022

ŞAHİN A., ESENDAęLI G., Berksöz M., Özgen H., DAęLIKOCA E. D., ÇAPAN Y., Nano-İmmünoterapi: Kanser Hücreleri ve Tümörle İlişkili Makrofajların Hücre İçi Hedeflenmesi (Nano-Immunotherapy: Intracellular Targeting of Cancer Cells and TAMs), 2018 - 2022

Patent

Şahin A., NAR ESASLI PASTİL FORMÜLASYONU VE BUNUN HAZIRLANMASI İÇİN BİR YÖNTEM, Patent, CHAPTER A Human Needs, The Invention Recourse Number: 2023/019500 , Standard Registration, 2023

ŞAHİN A., DERİ TEMASI İLE TETİKLENEN KORUYUCULU OTO ENJEKTÖR, Patent, CHAPTER F Mechanical engineering; Lighting; Heating; Weaponry; Destroyed Materials, Standard Registration, 2023

ŞAHİN A., A LONG-ACTING G-CSF FOR PREVENTING NEUTROPENIA OR REDUCING DURATION OF NEUTROPENIA, Patent, CHAPTER C Chemistry; Metallurgy, Standard Registration, 2023

ŞAHİN A., A stable lyophilized formulation for hybrid fc fused g-csf, Patent, CHAPTER C Chemistry; Metallurgy, Standard Registration, 2022

ŞAHİN A., Stable hybrid fc fusion g-csf formulation, Patent, CHAPTER C Chemistry; Metallurgy, Standard Registration, 2018